CONSULTING SERVICES AGREEMENTConsulting Services Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Delaware
This Consulting Services Agreement (“Agreement”) is made effective the 1st day of April 2009 (the “Effective Date”), by and between Emergent BioSolutions Inc. (“Emergent”), a Delaware corporation, with offices at 2273 Research Boulevard, Suite 400, Rockville, Maryland 20850, and The Hauer Group (“Consultant”), located at 7850 Southdown Road, Alexandria, VA 22308, Emergent and Consultant are sometimes hereinafter referred to in the singular as “Party” and collectively as the “Parties”.
ContractLoan Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Maryland
EMERGENT BIOSOLUTIONS INC. Restricted Stock Unit Agreement Amended and Restated 2006 Stock Incentive PlanRestricted Stock Unit Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Unit Agreement is made as of the Agreement Date between Emergent BioSolutions Inc. (the “Company”), a Delaware corporation, and the Participant.
AMENDMENT NO. 3 to the PRODUCT SUPPLY AGREEMENTProduct Supply Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
This Amendment No. 3 (the "Amendment"), is entered into by and between Talecris Biotherapeutics, Inc., headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box 110526, Research Triangle Park, North Carolina 27709 ("Talecris") and Emergent Product Development Gaithersburg Inc. with an address of 300 Professional Drive, Gaithersburg, MD 20879 ("Emergent" collectively, with Talecris, the "Parties," and each individually, a "Party"). All terms not defined herein shall have the meaning set forth in the Master Agreement (as defined below).
Product Supply AgreementProduct Supply Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
This Amendment No. 4 (“Amendment”), effective as of November 17, 2009 (“Effective Date”), is entered into by and between Talecris Biotherapeutics, Inc. (“Talecris”), with a business address of 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box 110526, Research Triangle Park, North Carolina 27709, and Emergent Product Development Gaithersburg Inc. (“Emergent”), with a business address of 300 Professional Drive, Gaithersburg, Maryland 20879. For the purposes of this Amendment, Emergent and Talecris shall each be deemed a “Party” and together the “Parties”.
AMENDMENT NO. 1 to the PRODUCT SUPPLY AGREEMENTProduct Supply Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Delaware
This Amendment No. 1 (the "Amendment"), effective as of December 19, 2006 (the “Effective Date”), is entered into by and between Talecris Biotherapeutics, Inc., headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box 110526, Research Triangle Park, North Carolina 27709 ("Talecris") and Emergent Product Development Gaithersburg Inc. ("Emergent" collectively, with Talecris, the "Parties," and each individually, a "Party"). All terms not defined herein shall have the meaning set forth in the Master Agreement (as defined below).
First Addendum to Product Supply AgreementProduct Supply Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
This First Addendum (this "Addendum") to that certain Product Supply Agreement dated June 12, 2006, as previously amended on December 19, 2006, June 25, 2007, and August 29, 2007, and as hereinafter amended from time to time (the "Agreement"), is entered into as of August 15, 2009, and effective as of September 1, 2009 (the "Addendum Effective Date"), by and between Talecris Biotherapeutics, Inc., ("Talecris") headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box 110526, Research Triangle Park, North Carolina 27709 and Emergent Product Development Gaithersburg Inc. ("Emergent"), a Delaware corporation having offices at 300 Professional Drive, Gaithersburg, MD 20879. For the purposes of this Addendum, Emergent and Talecris shall each be deemed a "Party" and together the "Parties." All terms not defined herein shall have the meaning set forth in the Agreement.
AMENDMENT NO. 2 to the Product Supply AgreementProduct Supply Agreement • March 5th, 2010 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 (the "Amendment"), effective as of June 25, 2007 (the "Effective Date"), is entered into by and between Talecris Biotherapeutics, Inc., headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box 110526, Research Triangle Park, North Carolina 27709 ("Talecris") and Emergent Product Development Gaithersburg Inc. with an address of 300 Professional Drive, Gaithersburg, MD 20879 ("Emergent" collectively, with Talecris, the "Parties," and each individually, a "Party"). All terms not defined herein shall have the meaning set forth in the Master Agreement (as defined below).
